相似文献
1
Novel targeted therapies for eosinophil-associated diseases and allergy.
Annu Rev Pharmacol Toxicol. 2015;55:633-56. doi: 10.1146/annurev-pharmtox-010814-124407. Epub 2014 Oct 17.
2
Eosinophils as a pharmacological target for the treatment of allergic diseases.
Curr Opin Pharmacol. 2014 Aug;17:71-80. doi: 10.1016/j.coph.2014.07.014. Epub 2014 Aug 14.
3
Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders.
Immunol Allergy Clin North Am. 2020 Nov;40(4):649-665. doi: 10.1016/j.iac.2020.07.001. Epub 2020 Sep 12.
4
Anti-allergic therapies: effects on eosinophil progenitors.
Pharmacol Ther. 2002 Jul;95(1):63-72. doi: 10.1016/s0163-7258(02)00233-4.
5
Biological Modulators in Eosinophilic Diseases.
Clin Rev Allergy Immunol. 2016 Apr;50(2):252-72. doi: 10.1007/s12016-014-8444-9.
6
Targeting eosinophils in allergy, inflammation and beyond.
Nat Rev Drug Discov. 2013 Feb;12(2):117-29. doi: 10.1038/nrd3838. Epub 2013 Jan 21.
7
CD28 and secretory immunoglobulin A-dependent activation of eosinophils: inhibition of mediator release by the anti-allergic drug, suplatast tosilate.
Clin Exp Allergy. 2004 Sep;34(9):1379-87. doi: 10.1111/j.1365-2222.2004.02036.x.
8
Indomethacin inhibits eosinophil migration to prostaglandin D2 : therapeutic potential of CRTH2 desensitization for eosinophilic pustular folliculitis.
Immunology. 2013 Sep;140(1):78-86. doi: 10.1111/imm.12112.
9
The activity of medicinal plants and secondary metabolites on eosinophilic inflammation.
Pharmacol Res. 2010 Oct;62(4):298-307. doi: 10.1016/j.phrs.2010.04.005. Epub 2010 May 5.
10
Mast cell and eosinophil surface receptors as targets for anti-allergic therapy.
Pharmacol Ther. 2017 Feb;170:37-63. doi: 10.1016/j.pharmthera.2016.10.010. Epub 2016 Oct 20.
引用本文的文献
1
Evidence of Inflammatory Network Disruption in Chronic Venous Disease: An Analysis of Circulating Cytokines and Chemokines.
Biomedicines. 2025 Jan 9;13(1):150. doi: 10.3390/biomedicines13010150.
2
Childhood blood eosinophils and symptoms of allergic disorders: a cross-sectional study in Southern China.
Ann Med. 2022 Dec;54(1):2929-2940. doi: 10.1080/07853890.2022.2134584.
3
Chronic Venous Disease during Pregnancy Causes a Systematic Increase in Maternal and Fetal Proinflammatory Markers.
Int J Mol Sci. 2022 Aug 11;23(16):8976. doi: 10.3390/ijms23168976.
4
Eosinophils in skin diseases.
Semin Immunopathol. 2021 Jun;43(3):393-409. doi: 10.1007/s00281-021-00868-7. Epub 2021 Jun 7.
5
Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity.
Semin Immunopathol. 2021 Jun;43(3):423-438. doi: 10.1007/s00281-021-00863-y. Epub 2021 May 30.
6
Regulation of eosinophil functions by autophagy.
Semin Immunopathol. 2021 Jun;43(3):347-362. doi: 10.1007/s00281-021-00860-1. Epub 2021 May 21.
7
Physiology and pathology of eosinophils: Recent developments: Summary of the Focus Workshop Organized by DGAKI.
Scand J Immunol. 2021 Jun;93(6):e13032. doi: 10.1111/sji.13032. Epub 2021 Mar 11.
8
Apoptosis of Eosinophil Granulocytes.
Biology (Basel). 2020 Dec 10;9(12):457. doi: 10.3390/biology9120457.
9
The Cellular Functions of Eosinophils: Collegium Internationale Allergologicum (CIA) Update 2020.
Int Arch Allergy Immunol. 2020;181(1):11-23. doi: 10.1159/000504847. Epub 2019 Nov 29.
10
Pharmacotherapies for the Treatment of Eosinophilic Esophagitis: State of the Art Review.
Drugs. 2019 Sep;79(13):1419-1434. doi: 10.1007/s40265-019-01173-2.
本文引用的文献
1
The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders.
J Allergy Clin Immunol. 2014 May;133(5):1439-47, 1447.e1-8. doi: 10.1016/j.jaci.2013.11.041. Epub 2014 Feb 13.
2
Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia.
Clin Cancer Res. 2014 Apr 1;20(7):1735-40. doi: 10.1158/1078-0432.CCR-13-1283. Epub 2014 Feb 5.
3
Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin.
Mol Cancer. 2014 Jan 28;13:17. doi: 10.1186/1476-4598-13-17.
4
Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib.
Clin Lymphoma Myeloma Leuk. 2014 Jun;14(3):186-96. doi: 10.1016/j.clml.2013.11.002. Epub 2013 Nov 14.
5
Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
BioDrugs. 2014 Feb;28(1):107-20. doi: 10.1007/s40259-013-0082-x.
6
Current clinical indications for plerixafor.
Transfus Med Hemother. 2013 Aug;40(4):246-50. doi: 10.1159/000354229. Epub 2013 Jul 19.
7
CD8(+) T cells producing IL-3 and IL-5 in non-IgE-mediated eosinophilic diseases.
Allergy. 2013 Dec;68(12):1622-5. doi: 10.1111/all.12311. Epub 2013 Nov 11.
8
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors.
Cancer Chemother Pharmacol. 2014 Feb;73(2):363-71. doi: 10.1007/s00280-013-2361-0. Epub 2013 Dec 3.
9
Role of periostin, FENO, IL-13, lebrikzumab, other IL-13 antagonist and dual IL-4/IL-13 antagonist in asthma.
Expert Opin Biol Ther. 2014 Feb;14(2):165-81. doi: 10.1517/14712598.2014.859673. Epub 2013 Nov 28.
10
The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.
Clin Exp Allergy. 2014 Jan;44(1):38-46. doi: 10.1111/cea.12220.
Zotero 插件